Avinash Vyas, MD
Internal Medicine · Oklahoma City, OKNPI 1902878739
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,248 of the $1,803 with a category attached, or 69.2%. 21 manufacturers reported payments, led by Braintree Laboratories, Inc. at 31.5% of the total. Reporting peaked in 2022 at $511 and has fallen 74.9% since, to $129 in 2025.
Across 66 payments — averaging $27.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Braintree Laboratories, Inc.$567
- AbbVie$212
- Abbott$156
- AstraZeneca$154
- Global Blood Therapeutics, Inc.$132
- Bayer$116
- plus $465 from 15 others
What the payments were for
- Food & beverage$1,24869%
- Gifts$55431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Braintree Laboratories, Inc. | 9 | $567 |
| AbbVie(2 entities) | 12 | $212 |
| Abbott | 8 | $156 |
| AstraZeneca | 3 | $154 |
| Global Blood Therapeutics, Inc. | 6 | $132 |
| Bayer | 1 | $116 |
| Dexcom, Inc. | 6 | $97 |
| Amgen | 4 | $66 |
| Medtronic | 3 | $45 |
| Boehringer Ingelheim | 2 | $44 |
| Daiichi Sankyo Inc. | 1 | $30 |
| GSK | 2 | $26 |
| Novartis | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Pfizer | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,803 in reported general payments places this provider in the 75th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 204 | $207,598 |
| OzempicSemaglutide | 69 | $96,000 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $83,618 |
| JardianceEmpagliflozin | 66 | $74,393 |
| Tresiba Flextouch U-200Insulin Degludec | 58 | $56,767 |
| JanuviaSitagliptin Phosphate | 53 | $43,502 |
| XareltoRivaroxaban | 38 | $35,144 |
| TradjentaLinagliptin | 33 | $27,817 |
| JanumetSitagliptin Phos/Metformin Hcl | 30 | $27,786 |
| CreonLipase/Protease/Amylase | 19 | $27,674 |
| LinzessLinaclotide | 34 | $24,693 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $21,159 |
| RybelsusSemaglutide | 12 | $20,853 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 95 | $19,138 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $14,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $19 | $213,494216 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $44 | $111,234110 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $26 | $94,258100 claims |
| AbbVieCreon, Linzess | $212 | $52,36753 claims |
| NovartisEntresto | $21 | $14,76123 claims |
| Lilly USA, LLCTrulicity | $14 | $14,15215 claims |
| Braintree Laboratories, Inc.Sutab | $567 | $13,90185 claims |
| AstraZenecaSymbicort | $154 | $9,09527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Oklahoma City
- Ryan MorganOklahoma City$235K
- Ali JafryOklahoma City$33K
- Samid FarooquiOklahoma City$20K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
- Zain Ul Abideen AsadOklahoma City$14K
- Stuart SchraderOklahoma City$12K
- Patrick GarrisonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.